Patent & IP news for February 1, 2016

Never too late: if you missed the IPKat last week from ipkitten.blogspot.com

Away last week or too busy to read the IPKat? As usual, don’t worry because our friend and colleague Alberto Bellan is back with his Never Too Late feature, now on its 83^{rd ...}

Share via E–mail | Twitter | Facebook

PhD Student Seminar at CIPA from ipkitten.blogspot.com

This moggy was thrilled to be able to attend last Thursday the inaugural running of an event at the Chartered Institute of Patent Attorneys - a seminar for PhD students.  CIPA had contacted everyone that it ...

Share via E–mail | Twitter | Facebook

Intellectual Property meets Antimonopoly law in Japan from ipkitten.blogspot.com

The IPKat is always delighted to receive IP-related news from outside Europe and the US, which tends to be the main focus of the blog.  This time, we have received news from Japan from Katfriend ...

Share via E–mail | Twitter | Facebook

As I suspected, the 2013 Nokia-Samsung patent deal is far from comprehensive: litigation still a possibility from www.fosspatents.com

In November 2013, Nokia and Samsung announced a five-year extension of an existing patent license agreement, with the financial terms left to determination by an arbitration panel. The scope was not announced, but back then ...

Share via E–mail | Twitter | Facebook

Interactive Television Patent Invalid Under 35 U.S.C. § 101 from docketreport.blogspot.com

The court granted defendant's motion to dismiss because the asserted claims of plaintiff’s interactive television application patent encompassed unpatentable subject matter and found that the claims were directed toward an abstract idea. "The ...

Share via E–mail | Twitter | Facebook

On Appeal, Abuse-Deterrent OxyContin Patents are Invalid from patentlyo.com

By Dennis Crouch Purdue Pharma v. Epic Pharma (Fed. Cir. 2016)[1] In an important Hatch-Waxman related decision, the Federal Circuit has affirmed the lower court’s holding that Purdue Pharma’s abuse deterrent OxyContin ...

Share via E–mail | Twitter | Facebook

Fintech patent competition: fierce, diverse, growing from ipcloseup.wordpress.com

Among the most watched areas for new patent value is financial technology, covering inventions in areas like authentication, mobile payments and wealth management. Fintech is among the few bright spots in the patent landscape, with ...

Share via E–mail | Twitter | Facebook

WHO Report: 45 Million New Jobs In Health Workforce By 2030 from www.ip-watch.org

A new report from the World Health Organization says there will be 45 million new jobs in the health workforce worldwide by the end of the UN Sustainable Development Goals in 2030. But most of ...

Share via E–mail | Twitter | Facebook

Purdue Pharma loses oxycontin appeal at the CAFC from ipbiz.blogspot.com

The CAFC affirmed SDNY in the oxycontin case:


For the foregoing reasons, we affirm the district
court’s invalidity determinations as to the low-ABUK
patents and the ’383 patent and the district court’s dis- ...

Share via E–mail | Twitter | Facebook

NewEgg Denied its Fees Again from patentlyo.com

Site Update v. CBS Corp and NewEgg (Fed Cir. 2016) Back in 2010, Site Update sued a broad set of companies for infringing its Reissued Patent No. RE40,683. The patent claims appear to broadly ...

Share via E–mail | Twitter | Facebook

Sean O'Connor: What happened to the "art" in "useful arts"? from writtendescription.blogspot.com

The constitutional justification for patents and copyrights is "[t]o promote the Progress of Science and useful Arts." In the late eighteenth century, "science" included all knowledge, and "useful arts" referred to technological rather than ...

Share via E–mail | Twitter | Facebook

Special Feature: UN High Level Panel On Access To Medicines – First Reactions, Process Explained from www.ip-watch.org

A high level panel of experts charged by United Nations secretary general to explore solutions to increase innovation and access to medicines in developing countries gave a briefing today to explain the process of the ...

Share via E–mail | Twitter | Facebook